Literature DB >> 22244677

State-of-the-art classification and multimodality treatment of malignant thymoma.

Hannah Koppitz1, Jürgen K Rockstroh, Heinrich Schüller, Jens Standop, Dirk Skowasch, Hans Konrad Müller-Hermelink, Ingo G H Schmidt-Wolf.   

Abstract

Thymomas are the most common tumors of the anterior mediastinum. Classification, treatment options and understanding of the pathophysiology of thymoma have changed over the past years. It is hoped that novel therapeutic strategies will lead to a survival benefit in these patients. It has turned out that patients with thymoma are best treated with multimodality therapy. In this review, a pathologist, an immunologist, a surgeon, a radiotherapist, a pneumologist and oncologists discuss the current status of classification and strategies for the treatment of thymoma patients.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22244677     DOI: 10.1016/j.ctrv.2011.11.010

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  15 in total

Review 1.  Management of large mediastinal masses: surgical and anesthesiological considerations.

Authors:  Wilson W L Li; Wim Jan P van Boven; Jouke T Annema; Susanne Eberl; Houke M Klomp; Bas A J M de Mol
Journal:  J Thorac Dis       Date:  2016-03       Impact factor: 2.895

Review 2.  Management of thymic tumors: a European perspective.

Authors:  Enrico Ruffini; Federico Venuta
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

3.  Pretreatment biopsy for histological diagnosis and induction therapy in thymic tumors.

Authors:  Jie Yue; Zhitao Gu; Zhentao Yu; Hongdian Zhang; Zhao Ma; Yuan Liu; Wentao Fang
Journal:  J Thorac Dis       Date:  2016-04       Impact factor: 2.895

4.  Myasthenia gravis in patients with thymoma affects survival rate following extended thymectomy.

Authors:  Zhefeng Zhang; Youbin Cui; Rui Jia; Lei Xue; Huagang Liang
Journal:  Oncol Lett       Date:  2016-05-05       Impact factor: 2.967

5.  Metronomics for thymic carcinoma.

Authors:  Jacobo Muñoz Del Toro; Patricia Cortez Castedo; Alfonso Cortés Salgado; M Eugenia Olmedo García; Pilar Garrido López
Journal:  Ecancermedicalscience       Date:  2014-12-18

6.  Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen.

Authors:  Francesco Perri; Salvatore Pisconti; Manuel Conson; Roberto Pacelli; Giuseppina Della Vittoria Scarpati; Antonio Gnoni; Carmine D'Aniello; Carla Cavaliere; Antonella Licchetta; Laura Cella; Mario Giuliano; Concetta Schiavone; Sara Falivene; Giuseppe Di Lorenzo; Carlo Buonerba; Vincenzo Ravo; Paolo Muto
Journal:  Onco Targets Ther       Date:  2015-06-08       Impact factor: 4.147

7.  Is thymomectomy sufficient for non-myasthenic early stage thymoma patients? A retrospective, single center experience.

Authors:  Aizemaiti Rusidanmu; Sha Huang; Xiayi Lv
Journal:  Thorac Cancer       Date:  2017-10-31       Impact factor: 3.500

8.  Expanding Spectrum of Toxoplasma gondii: Thymoma and Toxoplasmic Encephalitis.

Authors:  Daniel B Chastain; Joeanna I Sams; Gregory M Steele; Lindsey O Lowder; Carlos Franco-Paredes
Journal:  Open Forum Infect Dis       Date:  2018-07-07       Impact factor: 3.835

9.  [Pretreatment Biopsy for Histological Diagnosis and Induction Therapy in Thymic Tumors].

Authors:  Jie Yue; Zhitao Gu; Zhentao Yu; Hongdian Zhang; Zhao Ma; Yuan Liu; Wentao Fang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-07-20

10.  Deciphering tissue-based proteome signatures revealed novel subtyping and prognostic markers for thymic epithelial tumors.

Authors:  Xin Ku; Qiangling Sun; Lei Zhu; Zhitao Gu; Yuchen Han; Ning Xu; Chen Meng; Xiaohua Yang; Wei Yan; Wentao Fang
Journal:  Mol Oncol       Date:  2020-02-06       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.